

## IDENTIFYING PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (PSMA-POSITIVE MCRPC)

### INSTRUCTIONS

Meditech has reporting tools available to help identify patients with PSMA-positive MCRPC and assess clinical factors of these patients.

#### Step 1: Define Clinical Indications for Radioligand Therapy

- Work with clinical leads (oncologists, nuclear medicine specialists) to define eligibility criteria
- Criteria examples:
  - Confirmed metastatic castration-resistant prostate cancer (mCRPC)
  - Positive PSMA PET imaging results

#### Step 2: Configure Reports in EMR

- Action: Collaborate with the EMR administrator to create or modify reporting tools
- Filters to include:
  - Diagnosis codes (eg, ICD-10: C61 for prostate cancer)
  - Recent PSMA PET scan results or nuclear imaging flags

#### Step 3: Create Worklist or Report Outputs

- Output design: Generate a patient worklist with:
  - Patient name, medical record number (MRN)
  - Diagnoses
  - Imaging results
  - Lab values relevant to eligibility
  - Last oncology visit date

#### Step 4: Automate Report Scheduling

- Configure the system to run this report daily or weekly
- Ensure output is accessible by oncologists, referral coordinators, or relevant stakeholders

### LIMITATIONS AND NOTES

EHR, electronic health record; EMR, electronic medical record; HIT, health information technology; IS, information system; IT, information technology.

Novartis is not responsible for the implementation, testing, and ongoing operation of any EHR tools. If you have any questions pertaining to the use of these guides, please refer to your internal IT/IS department. These tools are not designed for, and have not been demonstrated to meet, any accreditation requirements. The instructions included in this brochure are applicable to the Meditech platform and are not guaranteed to work for any other software platforms.

Meditech® is a registered trademark of Medical Information Technology, Inc.

For more information on how the Novartis HIT Team can collaborate with your organization to identify shared priorities please email: [HIT.Novartis@novartis.com](mailto:HIT.Novartis@novartis.com)